Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas
Monaldi Archives for Chest Disease · 16.11.2026
DOI: 10.4081/monaldi.2026.3953 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Monaldi Archives for Chest Disease, online erschienen am 16.11.2026. Verfasst von Sujata Kaundal Parmar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rheumatoid arthritis (RA) and its treatments increase the susceptibility to tuberculosis (TB), mainly in TB-endemic settings. Latent TB infection (LTBI) screening is mandatory before biologic disease-modifying antirheumatic drugs. However, data on LTBI among RA patients receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), particularly from north India, are limited. Tuberculin skin testing (TST) may underestimate LTBI in patients with RA because of impaired cell-mediated immunity and reduced delayed-type hypersensitivity responses. In this prospective cross-sectional study, to exclude active TB, 146 consecutive adults with RA (ACR/EULAR 2010 criteria) receiving csDMARDs for ≥3 months underwent Mantoux TST (2 tuberculin units purified protein derivative; reading at 48-72 hours) and chest radiography . Using the conventional cut-off (≥10 mm), LTBI prevalence was 8.2% [12/146; 95% confidence interval (CI) 4.3-13.2%]. Using an immunosuppression-adjusted threshold (≥5 mm), prevalence was 23.3% (34/146; 95% CI 17.8-29.4%). The frequency of 0 mm TST induration was high (76.7%; 112/146). According to univariate analysis, LTBI positivity was linked to higher C-reactive protein (CRP), diabetes, fasting glucose ≥100 mg/dL, current smoking, smoking index >200, and urban residency. In multivariable logistic regression (outcome defined as ≥5 mm), smoking index >200 [adjusted odds ratio (OR) 11.47; 95% CI 1.52-86.6; p=0.018] and higher CRP (adjusted OR 1.036 per mg/L; 95% CI 1.006-1.070; p=0.018) remained independently associated with LTBI. Among RA patients on csDMARDs in a north Indian tertiary center, LTBI prevalence ranged from 8.2% (≥10 mm) to 23.3% (≥5 mm). Application of the ≥5 mm TST threshold substantially increased the estimated LTBI prevalence. The high proportion of participants with 0 mm TST induration suggests reduced TST responsiveness in this population. Further studies incorporating interferon-γ release assays are needed to determine the optimal LTBI screening strategy in patients with rheumatoid arthritis receiving csDMARD therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh.
- Department of General Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh.
- Department of Pulmonary Medicine and Critical Care, Indira Gandhi Medical College, Shimla, Himachal Pradesh.
- Department of Rheumatology, Indira Gandhi Medical College, Shimla, Himachal Pradesh.
Zitieren
APA
Parmar, S. K., Prem, G., Parmar, I., Sharma, S., & Sharma, V. (2026). Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2026.3953
Vancouver
Parmar SK, Prem G, Parmar I, Sharma S, Sharma V. Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas. Monaldi Archives for Chest Disease. 2026. doi:10.4081/monaldi.2026.3953
BibTeX
@article{Parmar2026,
author = {Parmar, Sujata Kaundal and Prem, Gautam and Parmar, Ingit and Sharma, Sunil and Sharma, Vikas},
title = {Latent tuberculosis infection in patients with rheumatoid arthritis receiving conventional synthetic disease-modifying antirheumatic drugs: a prospective cross-sectional study from the Himalayas},
journal = {Monaldi Archives for Chest Disease},
year = {2026},
doi = {10.4081/monaldi.2026.3953}
}
EUVIMED